GlassScriptPhysician profile
Gabriel Sanchez
NPI 1235525783
$3,136.60
in general payments reported to CMS, 2019-2025
10 companies · $801 in 2025
The $801 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.75 · 2020: $23.74 · 2021: $18.60 · 2022: $349 · 2023: $1,287 · 2024: $638 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.02 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $952.03 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $381.01 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $243.60 | 2025 | Qelbree |
| Tris Pharma INC | $173.64 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $131.95 | 2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $121.84 | 2022 | |
| Alkermes, INC. | $102.47 | 2022 | |
| Novo Nordisk INC | $24.44 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $18.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.